Coronavirus Infection, Pneumonitis
Conditions
Keywords
Hydroxychloroquine, coronavirus, prophylaxis, healthcare professional, outbreak
Brief summary
Healthcare professionals mainly doctors, nurses and their first degree relatives (spouse, father, mother, sister, brother, child) who have been started hydroxychloroquine(plaquenil) 200mg single dose repeated every three weeks plus vitaminC including zinc once a day were included in the study. Study has conducted on 20th of march. Main purpose of the study was to cover participants those who are facing or treating COVID19 infected patients in Ankara.
Detailed description
Healthcare professionals mainly doctors, nurses and their first degree relatives (spouse, father, mother, sister, brother, child) who have been started hydroxychloroquine(plaquenil) 200mg single dose repeated every three weeks plus vitaminC including zinc once a day were included in the study. Study has conducted on 20th of march. Main purpose of the study was to cover participants those who are facing or treating COVID19 infected patients.PArticipants, age, sex, BMI, smoking history, comorbid disease were also registered.
Interventions
health workers under risk who took this medications
Sponsors
Istinye University
Study design
Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
20 Years to 90 Years
Healthy volunteers
Yes
Inclusion criteria
1. person who are working as health professional with contact to known COVID positive case 2. Their first degree relatives (child, spouse or parents) 3. must be able to swallow tablets
Exclusion criteria
1. Already using plaquenil for other reasons (RA etc) 2. person with the diagnosis of COVID infection 3. Person with the condition may cause complications with this medication (severe CVD, av block, already has ophtalmological complications, organ failure of any degree etc). 4. Documented allergic history to chloroquine; 5. Documented history of hematological system diseases; 6. Documented history of chronic liver and kidney diseases; 7. Documented history of cardiac arrhythmia or chronic heart diseases; 8. Documented history of retina or hearing dysfunction; 9. Documented history of mental illnesses; 10. Use of digitalis due to the previous disease.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Protection against COVID-19 | 4 months | persons who took this medication should not have an infection |
Countries
Turkey (Türkiye)
Outcome results
None listed